Shopping Cart
- Remove All
- Your shopping cart is currently empty
Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $428 | In Stock | |
5 mg | $1,090 | In Stock | |
10 mg | $1,780 | In Stock | |
25 mg | $2,630 | In Stock | |
50 mg | $3,570 | In Stock |
Description | Cergutuzumab amunaleukin (CEA-IL2v) is a CEA-targeted IL-2 variant immunocytokine for combination cancer immunotherapy with immunostimulatory and anti-tumor activities for the study of solid cancers. |
In vitro | Cergutuzumab amunaleukin contains a single IL-2 variant (IL2V) part. The CD25 is abolished and blends to the high-end C-terminal. By removing the combination of CD25, Cergutuzumab amunaleukin can avoid priority activation of regulating T cells relative to immune effect cells. [1] Cergutuzumab amunaleukin activated the NK cells and converted into a killing of CEA-positive colon cancer cell line LS180, accompanied by the increase in the release of granase B, IFNγ, and RANTES, and the upward increase of CD25 and CD69 NK cells. [1] |
In vivo | Among the tumor-free mice treated with 0.5 and 2 mg/kg Cergutuzumab amunaleukin (i.v.; Once) the strong amplification of CD8+ T and NK cells after treatment. [1] |
Alias | RO 6895882, RG 7813, CEA-IL2v |
Molecular Weight | 162.05 kDa |
Cas No. | 1509916-03-3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.